Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win Read more
Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nod Read more
Regeneron ends eye disease trial for anti-CD3 antibody following safety review Read more
